Indinavir
From Proteopedia
(Difference between revisions)
| Line 13: | Line 13: | ||
{| class="wikitable" border="1" width="52%" style="text-align:center" | {| class="wikitable" border="1" width="52%" style="text-align:center" | ||
|- | |- | ||
| - | ! colspan="12" align="center"| HIV Protease Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]] | + | ! colspan="12" align="center"| HIV Protease Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]]<ref>DOI: 10.1046/j.1365-2125.2003.01736.x</ref> |
|- | |- | ||
! Parameter | ! Parameter | ||
| Line 29: | Line 29: | ||
|- | |- | ||
! [[Pharmaceutical_Drugs#Tmax|T<sub>max</sub>]] (hr) | ! [[Pharmaceutical_Drugs#Tmax|T<sub>max</sub>]] (hr) | ||
| - | ! | + | ! 2.67 |
! Tipranavir | ! Tipranavir | ||
! Indinavir | ! Indinavir | ||
| Line 42: | Line 42: | ||
|- | |- | ||
! [[Pharmaceutical_Drugs#Cmax|C<sub>max</sub>]] (ng/ml) | ! [[Pharmaceutical_Drugs#Cmax|C<sub>max</sub>]] (ng/ml) | ||
| - | ! | + | ! 5444 |
! Tipranavir | ! Tipranavir | ||
! Indinavir | ! Indinavir | ||
| Line 94: | Line 94: | ||
|- | |- | ||
! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr) | ! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr) | ||
| - | ! | + | ! 58000 |
! Tipranavir | ! Tipranavir | ||
! Indinavir | ! Indinavir | ||
Revision as of 06:54, 2 December 2010
|
Better Known as: Crixivan
- Marketed By: Merck & Co.
- Major Indication: Human Immunodeficiency Virus Infection
- Drug Class: HIV Protease Inhibitor
- Date of FDA Approval (Patent Expiration): 1996 (2014)
- 2006 Sales:
- Importance:
- The following is a list of Pharmacokinetic Parameters. See: Pharmaceutical Drugs for more information
Mechanism of Action
Pharmacokinetics
| HIV Protease Inhibitor Pharmacokinetics[1] | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Parameter | Ritonavir | Tipranavir | Indinavir | Saquinavir | Amprenavir | Fosamprenavir | Lopinavir | Ritonavir | Darunavir | Atazanavir | Nelfinavir |
| Tmax (hr) | 2.67 | Tipranavir | Indinavir | Saquinavir | Amprenavir | Fosamprenavir | Lopinavir | Ritonavir | Darunavir | Atazanavir | Nelfinavir |
| Cmax (ng/ml) | 5444 | Tipranavir | Indinavir | Saquinavir | Amprenavir | Fosamprenavir | Lopinavir | Ritonavir | Darunavir | Atazanavir | Nelfinavir |
| Bioavailability (%) | Ritonavir | Tipranavir | 65 | Saquinavir | Amprenavir | Fosamprenavir | Lopinavir | Ritonavir | Darunavir | Atazanavir | Nelfinavir |
| Protein Binding (%) | 99 | Tipranavir | 61 | 98 | Amprenavir | Fosamprenavir | Lopinavir | Ritonavir | Darunavir | Atazanavir | Nelfinavir |
| T1/2 (hr) | 4 | Tipranavir | 1.8 | 7-12 | Amprenavir | Fosamprenavir | Lopinavir | Ritonavir | Darunavir | Atazanavir | Nelfinavir |
| AUC (ng/ml/hr) | 58000 | Tipranavir | Indinavir | Saquinavir | Amprenavir | Fosamprenavir | Lopinavir | Ritonavir | Darunavir | Atazanavir | Nelfinavir |
| IC50 (nM) | Ritonavir | Tipranavir | Indinavir | Saquinavir | Amprenavir | Fosamprenavir | Lopinavir | Ritonavir | Darunavir | Atazanavir | Nelfinavir |
| Dosage (mg) | Ritonavir | Tipranavir | Indinavir | Saquinavir | Amprenavir | Fosamprenavir | Lopinavir | Ritonavir | Darunavir | Atazanavir | Nelfinavir |
| Metabolism | Hepatic (CYP3A4) | Tipranavir | Hepatic (CYP3A4) | Hepatic (CYP3A4) | Amprenavir | Fosamprenavir | Lopinavir | Ritonavir | Darunavir | Atazanavir | Nelfinavir |
References
